Active PriorityDeveloping
The FDA's Data on Mifepristone: A Trust Crisis
high consequencestill unresolvedUpdated 90d ago
Key takeaway: The credibility of the FDA is on the line as it navigates the complexities of mifepristone's data scrutiny in a polarized climate. Without robust verification, the agency’s findings may be easily contested.
